Inclusion Criteria:  -  To be eligible to enroll in the study, subjects must be:  In-Hospital 50 years of age or older Hospitalized for COVID-I9 symptoms At least one comorbidity. They have taken a COVID-19 diagnostic test. Peripheral 02 saturation below 94 on room air, nasal cannula or non-rebreather Patients may remain enrolled as long as they remain hospitalized for COVID-19 symptoms and receive a positive test panel for COVID-19 during the treatment phase Be able to provide consent.  Exclusion Criteria:  -  To be eligible to enroll in the study, subjects must not:  Require ventilatory support at the time of enrollment. Concurrent pulmonary bacterial infection Taking Light Sensitive Medications Have Lupus Diagnosis Enrolled in an existing Covid-19 Trial Taking In-patient Vitamin oral Supplementation Severe mental or medical disability History of melanoma or dysplastic nevus syndrome Prisoner Active tuberculosis or Cystic Fibrosis, Severe Chronic Obstructive Pulmonary Disease (COPD) or Pulmonary Fibrosis requiring home supplemental oxygen Pre-existing pulmonary hypertension INR > 2, LFT 6 times greater than baseline Stage 3b CKD or ESRD diagnosis before COVID-19 onset Evidence of cirrhosis Evidence of pre-existing vascular disorder or coagulopathy Irreversible bleeding disorder Patients who are not full code Taking oral light sensitizing medications (See Appendix) or using light sensitizing topical medication in the phototherapy treatment zones Taking in patient or at home Vitamin D supplementation Have any photosensitive skin disorder such as Systemic Lupus Erythematosus, Porphyria or Pseudoporphyria, Polymorphous Light Eruption Xeroderma Pigmentosa, Chronic actinic dermatitis, Hydroa vacciniforme, Dermatomyositis Bloom Syndrome, Rothmund Thomas syndrome, Cockayne Syndrome Requiring oxygen supplementation via CPAP/BiPAP, ventilator support, High Flow Nasal Prong therapy (HFNP) Concurrent pulmonary bacterial infection at the time of enrollment Previous hospital admission for COVID-19 symptoms